Articles tagged with Drug Studies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
The American Geriatrics Society released its second updated Beers Criteria, which identifies over 40 potentially problematic medications for older adults. The guidelines also provide alternative therapies and guidance on best practices for implementing recommendations.
A Yale University study found that varenicline was 46% more effective in women after three months of treatment, leading to higher abstinence rates. The drug's effectiveness for women may be due to differences in the nicotine receptor system in the brain.
A five-year trial found that emergency department-based brief interventions significantly reduced underage drinking and related consequences among patients aged 14-20. The study suggests that a single-session intervention can play a role in decreasing underage drinking among youth.
A new study found that US clinical trials of chronic pain drugs experienced a steady increase in placebo response over time. The analysis revealed that trials conducted only in the US showed this trend, whereas European and Asian trials did not.
A study published in Sexual Medicine found that postcoital dysphoria affects 46% of women, leading to feelings of melancholy or depression. The study also revealed a relationship between negative emotions and potential evolutionary functions.
A study of Danish patients undergoing noncardiac surgery found that use of β-blockers was associated with increased risk for major adverse cardiovascular events (MACEs) and death. The results suggest that perioperative management of patients with hypertension should receive specific attention in clinical practice.
A 45-year study of 179 individuals with childhood-onset epilepsy found that patients attain excellent seizure outcomes, but often exhibit abnormal neurologic signs. These signs may be a risk factor for future stroke and cognitive impairment, highlighting the need for ongoing monitoring and care.
Researchers discovered that excess IGFBP3 damages colonic stem cells, leading to intestinal lining damage and chronic gastrointestinal symptoms. A biopharmaceutical blocking circulating levels of the protein has shown promising results in reversing colon damage in diabetic mice.
A large international team of researchers is investigating the genetic factors behind transplant successes and failures. The project, iGeneTRAiN, has generated genomics data for over 32,000 organ donors and recipients, aiming to discover genetic variants that lead to rejection and other complications.
A six-week clinical trial found that reduced-nicotine cigarettes decreased nicotine exposure and dependence, as well as the number of cigarettes smoked per day. The study suggests potential benefits for smoking cessation and reducing tobacco-related harm.
A team from Penn Dental Medicine successfully produced a shelf-stable, low-cost drug using freeze-dried lettuce leaves, which promotes tolerance to clotting factors for hemophilia patients. The study confirms the viability of plant-based biopharmaceutical production on a commercial scale.
A recent study published in PLOS ONE found that psychotherapy's effectiveness in treating depression is often overstated due to publication bias. The research team analyzed unpublished data from 55 clinical trials and concluded that the treatment works but its benefits are inflated by selective publication of positive results.
The Collaboration for Alzheimer's Prevention (CAP) brings together researchers from six clinical trials to share information, resources, and expertise. CAP aims to accelerate the evaluation of preclinical Alzheimer disease treatments through data harmonization and standardization.
A new study from Mayo Clinic shows that simple conversation cards can dramatically improve patients' and clinicians' satisfaction with antidepressant discussions. The tool increased patients' comfort in making decisions by 5 points and their satisfaction likelihood by 2.4-fold, while also improving physicians' decision-making comfort a...
A two-drug combination of venlafaxine and aripiprazole relieved depression in 44% of treatment-resistant patients over 60, while reducing suicidal thoughts. The study's findings suggest that older adults may respond to this treatment strategy, offering new hope for those with hard-to-treat depression.
A new study suggests that a diabetes medication could be used to treat alcohol dependence, with results showing a 30-40% reduction in consumption and prevention of relapse. The medication works by interfering with the hormone GLP-1, which regulates food intake and reward centers.
Researchers found that combining antidepressants with blood thinners increases autophagy in cancer cells, causing them to die. This combination therapy doubled the lifespan of mice with early-stage brain cancer, but further study is needed to confirm its effectiveness.
Two US studies published in The BMJ reveal a significant increase in drugs approved via expedited pathways, raising concerns about efficacy and safety. The findings suggest that most new drugs may not be significantly more effective than existing products.
A new study published in the Journal of Oncology Practice found that patients participating in stage III renal cell cancer drug trials are often younger and healthier than those who ultimately receive the drugs. The study highlights concerns about the direct applicability of trial data, particularly for patients with more advanced canc...
A NAMS panel recommends behavioral approaches like cognitive-behavioral therapy and clinical hypnosis as effective in reducing hot flash symptoms. Nonhormonal prescription medications, such as SSRIs and gabapentinoids, are also recommended for their mild to moderate improvements.
A new study published in Diabetologia shows that taking blood pressure medications at bedtime halves the risk of developing type 2 diabetes in hypertensive patients. The research found a 57% decrease in risk with nighttime treatment compared to morning treatment.
A 10-week randomized trial showed significantly reduced measures of agitation in patients treated with dextromethorphan-quinidine, with an average 51% reduction compared to placebo. The combination medication was associated with a lower risk of adverse events and cognitive impairment.
A review of 54 studies from 20 countries found that people in addiction treatment have a much higher smoking rate, 84% vs 31%, for the general population. The study suggests that addressing tobacco use is crucial to improve substance treatment outcomes.
The EORTC 1320 trial, coordinated by the EORTC Brain Tumor Group, aims to assess the efficacy and safety of YONDELIS (trabectedin) compared to standard care in patients with recurrent grade II or III meningioma. The study plans to accrue 86 patients across 47 sites in ten countries.
A new study found that patients on one-fourth the suggested dose of beta-blockers survived at the same rate or even better than those on higher doses, increasing survival by 20-25%. The research suggests that beta-blocker dosing needs to be personalized for individual patients.
A new animal study reveals that traumatic brain injury (TBI) affects the body as well as the brain, leading to chronic inflammation, nerve cell death, and reduced blood flow. Treatment with hypertension drugs blocks the production of proteins related to inflammation, potentially healing the brain.
A Mayo Clinic study examines the adoption and cessation of calcium magnesium (CaMg) use for oxaliplatin-induced neuropathy, highlighting the challenges of translating research into clinical practice. The study reveals a decade-long cycle of rapid changes in treatment, driven by emerging evidence and public perception.
A new study found no significant differences in self-care activities and diabetes test results between patients of nurse prescribers and non-prescribers. Despite the benefits of prescribing qualification, budget concerns may lead primary care practices to invest in lower-paid nurses.
The Women's Antiretroviral Efficacy and Safety Study found that women receiving Stribild had a higher rate of HIV suppression compared to those on ritonavir-boosted atazanavir plus Truvada. No one on Stribild developed resistant mutations, in contrast to three women in the comparator group.
A recent Alberta study found that pharmacist-led care can significantly reduce blood pressure in patients, with patients receiving enhanced care being twice as likely to reach their recommended targets. The RxACTION project demonstrated the effectiveness of pharmacists' independent prescribing and active patient management.
A new study published in PLOS ONE found that higher doses of hydrocortisone are not associated with brain injury or neurodevelopmental impairments in extremely low birthweight infants. However, the study suggests that lower doses of hydrocortisone may improve cognitive outcomes.
A clinical trial of romidepsin, an HDAC inhibitor, found that it can reverse HIV latency in individuals on long-term antiretroviral therapy. The treatment did not negatively affect T-cell function, and increased plasma HIV-1 RNA was detectable in five of six participants.
A Phase 2a trial will assess the safety and immunogenicity of IDRI's TB vaccine candidate in 60 participants in South Africa, who have previously had active TB. The trial aims to reduce TB recurrence after treatment, a major threat to TB control programs.
A reanalysis of a 2001 study on antidepressants found that popular drug paroxetine is neither safe nor effective for adolescents with depression. The new results contradict the original research and have important implications for research and practice.
A University of Adelaide-led reanalysis of Study 329 found that paroxetine was no more effective at relieving depression symptoms than a placebo, linked to 11 suicidal or self-harming behaviours
A new study published in PLOS Medicine found that electronic reminders can significantly improve tuberculosis treatment adherence in China. Patients who received electronic medication monitors missed only 17% of their doses, compared to 29.9% for those with no reminders and 27.3% for those receiving text message reminders.
A cluster randomized controlled trial found that electronic reminders via medication monitors and text messages improved tuberculosis treatment adherence, with non-adherent rates decreasing from 29.9% to 17.0%. The study suggests innovative approaches to improve TB treatment outcomes in remote areas.
A new classification system for gout has been developed to standardize its diagnosis and treatment. The system uses evidence-based criteria and has been validated by comparing it to existing published criteria, outperforming them in performance.
The American College of Physicians released a guide for appropriate use of peripherally inserted central catheters (PICCs) to address growing concerns over their use in hospitals. The guide highlights the potential for complications like thrombosis and infection, as well as variation in their use among patients.
PharmaMar presents new data for YONDELIS (trabectedin) in soft tissue sarcoma and solid tumors, including final overall survival analysis and real-world data from a large prospective phase IV study. Additionally, early clinical studies show synergistic activity for PM1183 in combination with paclitaxel or cisplatin.
Researchers found that high-dose resveratrol stabilized a biomarker associated with Alzheimer's disease progression. The study, involving 119 participants, also showed that resveratrol was safe and well-tolerated, but its effects on brain volume were unclear.
A team of researchers at the University of Kansas has identified a potential neuroprotective mechanism for Alzheimer's disease, focusing on the ApoE2 gene. The study suggests that ApoE2 carriers may be resistant to Alzheimer's disease due to enhanced brain energy metabolism.
Researchers have found a new strategy to eliminate HIV by reactivating latent infected cells using a class of drugs called Smac mimetics. The approach, which has shown promising results in clinical trials for cancer, may lead to a safe and effective treatment to cure the virus.
A University of Colorado Cancer Center study found that 41% of open lung cancer clinical trials excluded patients with previously treated CNS disease, while 26% allowed those with untreated CNS involvement. The study suggests that current practice may be based on habit rather than scientific rationale.
Recent small studies suggest psychedelic drugs like LSD and psilocybin may help reduce anxiety, PTSD symptoms, and alcohol addiction. However, more research is needed to confirm these findings and determine clinical application.
The Phase I study confirms the therapeutic dose and safety profile of SCYX-7158, a first oral drug candidate specifically developed to combat human African trypanosomiasis. The study results translate into prolonged exposure with just one dose, targeting the late stage of the disease where the parasite crosses the blood-brain barrier.
Researchers at Scripps Research Institute have received a nearly $4.5 million grant with the possibility of up to $10 million to complete preclinical studies on a new anti-migraine drug candidate. The compound has shown promising results in treating stress-induced migraine and may be developed into a once-a-day pill.
ESC Congress 2015 saw a record-breaking attendance of 32,773 registrations, featuring 28 clinical Hot Line presentations, 18 Clinical Trial Updates, and 20 Registry studies. Key findings included the use of spironolactone for resistant hypertension and its positive implications for clinical practice.
A study published in JAMA found that finerenone significantly reduces albuminuria in patients with diabetes and kidney disease. The medication also shows a lower risk of hyperkalemia compared to other treatments.
Researchers at Massachusetts General Hospital found that urate stimulates astrocytes to activate an antioxidant pathway believed to have a role in several neurodegenerative disorders. A phase 3 trial of a urate-elevating drug, led by Dr. Michael Schwarzschild, is planned to enroll 270 patients with early-stage Parkinson's disease.
Dr. Peter Berger suggests that the expensive drug offers no clear safety benefits over heparin, which is widely used and effective in lower doses. The MATRIX Trial found no advantages of bivalirudin over heparin in preventing bleeding complications during cardiac stent placement.
A randomized controlled trial found that a self-management support service improved patients' symptoms and recovery scores. The program combined behavioral therapy with recovery-oriented approach, focusing on achieving life goals despite symptoms. Participants showed significant improvements compared to usual care.
The ELIXA trial demonstrated that lixisenatide, a GLP-1 receptor agonist, did not increase or decrease the rate of cardiovascular events compared to placebo. The study found a modest benefit in weight gain, but also identified patients with heart failure as being at high risk of all-cause death.
A new analysis of the TECOS study adds heart failure data to confirm sitagliptin's cardiovascular safety. The findings provide reassurance to patients and prescribers about the drug's risk profile.
A new study found that antiarrhythmia drug therapy after radiofrequency catheter ablation for atrial fibrillation does not reduce arrhythmia recurrence rates at one year. The treatment, which had shown a temporary benefit in earlier studies, lost its effectiveness once the medication was stopped.
A new Phase III clinical trial indicates cariprazine may treat negative symptoms associated with schizophrenia, including lack of emotion and social withdrawal. Researchers found a statistically significant improvement in the PANSS-NFS scale relative to risperidone after 26 weeks of treatment.
The CIRCUS trial found that cyclosporine did not reduce all-cause death, hospitalization for heart failure, or adverse left ventricular remodelling in STEMI patients undergoing PCI. The study suggested that targeting reperfusion injury remains a major challenge for PCI cardiologists.
A recent trial published at ESC Congress 2015 found that patient education programs did not significantly impact apixaban adherence. Adherence rates were high across both the control and education groups, with minimal difference observed between the two.
A new study published in the American Journal of Psychiatry has discovered a predictive fMRI-derived measure that significantly predicts patients' response to antipsychotic medication. This breakthrough enables the use of brain scans as a tool for guiding treatment and improving patient outcomes.
Daratumumab, a monoclonal antibody targeting CD38, showed significant promise against difficult-to-treat disease in patients with advanced multiple myeloma, achieving durable responses in 36% of patients, including complete remissions and very good partial responses.